CO2020010269A2 - Variantes fc con unión mejorada a fcrn y semivida prolongada - Google Patents

Variantes fc con unión mejorada a fcrn y semivida prolongada

Info

Publication number
CO2020010269A2
CO2020010269A2 CONC2020/0010269A CO2020010269A CO2020010269A2 CO 2020010269 A2 CO2020010269 A2 CO 2020010269A2 CO 2020010269 A CO2020010269 A CO 2020010269A CO 2020010269 A2 CO2020010269 A2 CO 2020010269A2
Authority
CO
Colombia
Prior art keywords
variants
life
binding polypeptides
fcrn binding
long half
Prior art date
Application number
CONC2020/0010269A
Other languages
English (en)
Inventor
Huawei Qiu
Brian Mackness
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CO2020010269A2 publication Critical patent/CO2020010269A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción proporciona polipéptidos de unión (p. ej., anticuerpos e inmunoadhesinas) que comprenden un dominio de Fc modificado. La presente descripción también proporciona ácidos nucleicos que codifican los polipéptidos de unión, vectores de expresión recombinantes, y células huésped para preparar tales polipéptidos de unión. También se proporcionan métodos de uso de los polipéptidos de unión descritos en este documento para tratar la enfermedad.
CONC2020/0010269A 2018-01-26 2020-08-20 Variantes fc con unión mejorada a fcrn y semivida prolongada CO2020010269A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862622468P 2018-01-26 2018-01-26
PCT/US2019/015204 WO2019147973A1 (en) 2018-01-26 2019-01-25 Fc variants with enhanced binding to fcrn and prolonged half-life

Publications (1)

Publication Number Publication Date
CO2020010269A2 true CO2020010269A2 (es) 2020-12-10

Family

ID=65520379

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0010269A CO2020010269A2 (es) 2018-01-26 2020-08-20 Variantes fc con unión mejorada a fcrn y semivida prolongada

Country Status (15)

Country Link
US (1) US20190263934A1 (es)
EP (1) EP3743441A1 (es)
JP (2) JP7399880B2 (es)
KR (1) KR20200115568A (es)
CN (1) CN111788221A (es)
AU (1) AU2019212638A1 (es)
BR (1) BR112020015006A2 (es)
CA (1) CA3089602A1 (es)
CO (1) CO2020010269A2 (es)
IL (1) IL276286A (es)
MX (1) MX2020007882A (es)
PH (1) PH12020551134A1 (es)
SG (1) SG11202006905YA (es)
TW (1) TW201940512A (es)
WO (1) WO2019147973A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210024620A1 (en) * 2019-07-25 2021-01-28 Genzyme Corporation Methods of Treating Antibody-Mediated Disorders with FcRn Antagonists
CN115867572A (zh) * 2020-05-11 2023-03-28 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物和使用方法
EP4204091A2 (en) * 2020-10-29 2023-07-05 Formycon AG Ace2 fusion proteins and uses thereof
US20230077531A1 (en) 2021-05-27 2023-03-16 Sanofi Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY
CA3227716A1 (en) 2021-08-20 2023-02-23 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
WO2023064841A1 (en) * 2021-10-13 2023-04-20 The Wistar Institute Of Anatomy And Biology Antibodies for use against sars-cov-2
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
US20240166750A1 (en) 2022-10-25 2024-05-23 Ablynx N.V. GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
BR0008758A (pt) * 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
EP1664116A4 (en) 2003-08-22 2009-06-03 Biogen Idec Inc IMPROVED ANTIBODIES WITH CHANGED EFFECTOR FUNCTION AND MANUFACTURING METHOD THEREFOR
JP2008510466A (ja) * 2004-08-19 2008-04-10 ジェネンテック・インコーポレーテッド エフェクター機能が変更しているポリペプチド変異体
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP2845865A1 (en) * 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
EP1896503B1 (en) * 2005-05-31 2014-10-29 Board of Regents, The University of Texas System IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2010068722A1 (en) * 2008-12-12 2010-06-17 Medimmune, Llc Crystals and structure of a human igg fc variant with enhanced fcrn binding
WO2011076922A1 (en) * 2009-12-23 2011-06-30 Synimmune Gmbh Anti-flt3 antibodies and methods of using the same
WO2011089211A1 (en) * 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
WO2013047748A1 (ja) * 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
CN105164157B (zh) * 2013-04-29 2024-05-28 豪夫迈·罗氏有限公司 Fc-受体结合的修饰的非对称抗体及使用方法
ES2749383T3 (es) * 2014-11-06 2020-03-20 Hoffmann La Roche Variantes de la región Fc con unión al FcRn modificada y procedimientos de uso
RU2017120358A (ru) * 2014-11-10 2018-12-13 Ф.Хоффманн-Ля Рош Аг Анти-il-1-бета антитела и способы их применения

Also Published As

Publication number Publication date
CN111788221A (zh) 2020-10-16
BR112020015006A2 (pt) 2020-12-29
TW201940512A (zh) 2019-10-16
CA3089602A1 (en) 2019-08-01
MX2020007882A (es) 2020-12-03
JP2024026255A (ja) 2024-02-28
WO2019147973A1 (en) 2019-08-01
IL276286A (en) 2020-09-30
EP3743441A1 (en) 2020-12-02
RU2020128177A (ru) 2022-02-28
AU2019212638A1 (en) 2020-09-17
KR20200115568A (ko) 2020-10-07
JP2021511830A (ja) 2021-05-13
SG11202006905YA (en) 2020-08-28
US20190263934A1 (en) 2019-08-29
JP7399880B2 (ja) 2023-12-18
PH12020551134A1 (en) 2021-05-31

Similar Documents

Publication Publication Date Title
CO2020010269A2 (es) Variantes fc con unión mejorada a fcrn y semivida prolongada
CO2021002907A2 (es) Constructos de anticuerpos para cldn18.2 y cd3
MX2023007211A (es) Anticuerpos antimiostatina y metodos de uso.
CO2019003809A2 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso
DOP2019000011A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
ECSP15014133A (es) Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
CL2021001835A1 (es) Neoantígenos prostáticos y sus usos.
EA202092093A1 (ru) Композиции и способы перепрограммирования tcr с применением слитых белков
BR112022000319A2 (pt) Heterodímeros e métodos de uso dos mesmos
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
BR112021016272A2 (pt) Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos
AR115695A1 (es) Moléculas proteicas multifuncionales que comprenden decorina y uso de estas
EA201792274A1 (ru) Слитые молекулы вариант iii рецептора эпидермального фактора роста-мезотелин и способы их применения
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
PE20200487A1 (es) Proteinas de union al antigeno anti-jagged1
EA201790241A1 (ru) Эффективная селективность в отношении рекомбинантных белков
CO2020000231A2 (es) Composiciones inmunogénicas que comprenden cea muc1 y tert
BR112018005464A2 (pt) expressão de proteínas contendo fc
BR112023018832A2 (pt) Composições de proteínas de fusão quiméricas modificadas e métodos de uso das mesmas
CU20220017A7 (es) Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes
BR112019004017A2 (pt) proteínas quiméricas para direcionar dsrna
EA202191919A1 (ru) Неоантигены предстательной железы и их применение